2018•British Journal of HaematologyRequires access

Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma

Mohammed Junaid Hussain, Myra M Robinson, Issam S. Hamadeh, Justin R. Arnall, Manisha Bhutani, Shebli Atrash, Reed N. Friend, Mauricio Pineda‐Roman, James Thomas Symanowski, Saad Z. Usmani, Peter M. Voorhees

Open publisher page 13 citations

Abstract

The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 13 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Daratumumab, Pomalidomide, Medicine, Dexamethasone, Multiple myeloma, Oncology, Internal medicine, Refractory (planetary science)